BioHarvest Sciences (8MV0) 주식 개요는 이스라엘과 미국에서 생명공학 회사로 운영되고 있습니다. 자세히 보기8MV0 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장5/6과거 실적0/6재무 건전성4/6배당0/6강점공정 가치 추정치보다 낮은 61.1% 에서 거래수익은 매년 61.12% 증가할 것으로 예상됩니다.위험 분석지난 1년 동안 주주가 크게 희석되었습니다.의미 있는 시가총액이 없습니다(€75M)모든 위험 점검 보기8MV0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.2480.0% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m126m2016201920222025202620282031Revenue US$125.8mEarnings US$12.2mAdvancedSet Fair ValueView all narrativesBioHarvest Sciences Inc. 경쟁사GenicSymbol: KOSDAQ:A123330Market cap: ₩153.0bBeiersdorfSymbol: XTRA:BEIMarket cap: €15.9bFitLife BrandsSymbol: NasdaqCM:FTLFMarket cap: US$94.6mG&E Herbal BiotechnologySymbol: TPEX:4911Market cap: NT$2.0b가격 이력 및 성과BioHarvest Sciences 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$3.2452주 최고가US$10.8052주 최저가US$2.96베타1.371개월 변동-8.99%3개월 변동-15.63%1년 변동-38.87%3년 변동-33.40%5년 변동-57.92%IPO 이후 변동-2.91%최근 뉴스 및 업데이트공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026공시 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.공시 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7공시 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025공시 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.더 많은 업데이트 보기Recent updates공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026공시 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.공시 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7공시 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025공시 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.공시 • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.공시 • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025공시 • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025공시 • Jan 22Bioharvest Sciences Inc. Appoints Sharon Malka as Independent DirectorBioHarvest Sciences Inc. announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately. Sharon Malka brings a wealth of experience to BioHarvest, having held senior leadership positions with a number of international healthcare and technology companies. He is currently Chief Executive Officer of Dotz Nano Ltd., an Australian-based technology company focused on developing, manufacturing and commercializing advanced materials for diagnostics solutions. Mr. Sharon is currently on the Board of Directors of MediWound Limited, a Nasdaq-listed biopharmaceutical company, where he also previously served as both Chief Financial Officer and Chief Executive Officer. Prior to Mediwound, Sharon held the role of Partner at Variance Economic Consulting Ltd., a financial services consulting boutique focused on international technology company. Mr. Malka is a certified CPA and graduate of the Executive Education Program of Harvard Business School. He holds a B.Sc. in Business Administration and an M.B.A.공시 • Nov 27BioHarvest Sciences Inc. Launches VINIA Superfood Functional Tea LineBioHarvest Sciences Inc. announced the launch of its highly anticipated VINIA infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA® supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals. Tens of thousands of subscribers take VINIA daily to improve blood flow as a supplement in capsule form or through VINIA® Superfood coffee, which increases their dilation of arteries, improving blood flow and enhancing their physical energy and mental alertness. Now consumers can experience those same blood flow improvements together with a cup of great tasting VINIA Superfood Tea, featuring four premium blends: Black Tea, Green Tea, Matcha Green Tea and Cranberry Hibiscus Herbal Tea. BioHarvest's VINIA® SuperFood Infused Teas - which contain the equivalent piceid resveratrol contained in one capsule of VINIA® - deliver superior science, efficacy and taste. Third party blind taste testing shows BioHarvest's VINIA® infused teas outperformed leading English Breakfast and Green Tea brands. All the tea used in the VINIA SuperFood Infused Teas lineup are sourced from Rainforest Alliance certified farms. BioHarvest will launch its VINIA® infused tea line across major channels starting, December 7th, following a VIP launch commencing on November 25, 2024 for select existing VINIA® subscribers.New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.2m free cash flow). Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).공시 • Oct 23+ 1 more updateBioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024BioHarvest Sciences Inc. announced that they will report Q3, 2024 results on Nov 14, 2024공시 • Sep 20Bioharvest Sciences Inc. Announces Resignation of David Ryan as DirectorBioHarvest Sciences Inc. announced the resignation of David Ryan as a director of the Company. Mr. Ryan will remain a key member of the Company's management team, continuing to serve as Vice President of Investor Relations of the Company. Mr. Ryan resigned as a director of the Company in order for the Company to meet Nasdaq mandates to have a majority of independent directors in connection with its proposed application to list its common shares on the Nasdaq Stock Market.Reported Earnings • Aug 30Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.042 loss per share (improved from US$0.21 loss in 2Q 2023). Revenue: US$6.03m (up 119% from 2Q 2023). Net loss: US$687.0k (loss narrowed 76% from 2Q 2023). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.New Risk • Aug 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €91.2m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.2m). Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€91.2m market cap, or US$99.6m).공시 • Jun 21BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in fundingBioHarvest Sciences Inc. announced a private placement of up to 697,350 units at a price of CAD 9.82 per unit for the gross proceeds of CAD 6,847,977 on June 21, 2024. Each unit includes one common share, one-quarter (1/4) of a CAD 10.50 warrant, and one-quarter (1/4) of an CAD 15.77 Warrant. The Company will pay cash commissions or finders fees of up to 5% of the cash proceeds of the offering.Reported Earnings • Jun 05First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)First quarter 2024 results: US$0.48 loss per share (further deteriorated from US$0.057 loss in 1Q 2023). Revenue: US$5.34m (up 147% from 1Q 2023). Net loss: US$6.58m (loss widened US$5.83m from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.Reported Earnings • May 02Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)Full year 2023 results: US$0.027 loss per share (further deteriorated from US$0.025 loss in FY 2022). Revenue: US$12.7m (up 131% from FY 2022). Net loss: US$12.6m (loss widened 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공시 • Apr 05BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024.공시 • Jan 09BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024BioHarvest Sciences Inc. announced that they will report Q4, 2023 results on Mar 29, 2024공시 • Dec 27BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in fundingOn December 27, 2023, BioHarvest Sciences Inc., closed the transaction. The company raised CAD 1,836,383.28 in its second and final tranche closing. As a part of the transaction, the company paid a total of CAD 53,247.54 as commissions or finder's fees associated with this final tranche. The transaction was oversubscribed by CAD 122,873.26.공시 • Dec 14Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee ProductsBioHarvest Sciences Inc. announced that it has created a new "functional" coffee product line featuring VINIA Red Grape Superfood, its nutraceutical product.ens of thousands of subscribers take VINIA daily to improve blood flow, which enhances their physical energy and mental alertness, and now consumers can experience those same blood flow improvements conveniently together with one daily cup of great tasting VINIA Superfood coffee, now available at . These new VINIA coffee products are the first of three key delivery mechanisms implementing the 'VINIA Inside' Strategy. The BioHarvest Sciences Botanical Synthesis platform delivers non- GMO, fingerprint consistent plant cells with elicited levels of active phytochemicals not available in nature. All benefits and claims are supported by scientific studies and clinical trials. Superior Taste-- All product formulations are extensively taste-tested via blind quantitative taste test research versus market leaders. VINIA is clinically proven to significantly dilate arteries. It achieves this unique outcome by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which Act as a vasoconstrictor). BioHarvest currently has a Direct-to-Consumer focus, with 93% of VINIA sales occurring on VINIA.com being via subscription. BioHarvest also uses Amazon.com as a key channel to source new customers. Formulated by leading scientists and coffee connoisseurs, VINIA Superfood Coffee contains 100% premium Arabica beans and is infused with a matrix of the red grape polyphenols found in red wine, with zero alcohol. VINIA Superfood Coffee is available for online purchase in North America on company website. Each Medium Roast and Decaf VINIA Superfood Coffee Pod includes VINIA Red Grape Powder (23 mg of polyphenols including 6 mg of piceid resveratrol) which is equivalent to one VINIA capsule. VINIA® Superfood Coffee is compatible with Keurig and most single serve brewing systems. VINIA has no affiliation with Keurig Dr. Pepper Inc, "Keurig" and "K-Cup" is a registered trademark of Keurig Dr. Pepper Inc. VINIA Superfood functional coffees are expected to be available in 2024 in Nespresso compatible pods, and the Company has announced that it will add tea products to its Hot Beverages business, including black and green teas. The Company expects to release financial guidance on the new VINIA Superfood Coffee and Tea portfolio at the end of first quarter of 2024.공시 • Nov 30Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023BioHarvest Sciences Inc. revised revenue guidance for the year 2023. The company expects total revenue for 2023 to fall 27% short of the USD 17 Million revenue guidance provided by the Company in early 2023.Reported Earnings • Nov 30Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.009 loss in 3Q 2022)Third quarter 2023 results: US$0.004 loss per share (improved from US$0.009 loss in 3Q 2022). Revenue: US$3.24m (up 114% from 3Q 2022). Net loss: US$1.73m (loss narrowed 56% from 3Q 2022).공시 • Nov 30BioHarvest Sciences Inc. Provides Revenue Guidance for the Fourth Quarter 2023BioHarvest Sciences Inc. provided revenue guidance for the fourth quarter 2023. For the fourth quarter 2023, the company revenue range guidance of USD 4.2 million - USD 4.5 million.공시 • Oct 20BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in fundingBioHarvest Sciences Inc. announced a non-brokered private placement of convertible notes for the gross proceeds of CAD 12,000,000 on October 19, 2023. The notes will have a term of 24 months, and pay interest of 12% per annum. The convertible notes and accrued interest will be convertible at the option of the holder into common shares of the Issuer at a conversion price that is equal to the closing market price of the company’s common shares on the date of conversion less a discount of 20% but in any event, not less than CAD 0.24 per share or more than CAD 0.75 per share.Reported Earnings • Sep 03Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)Second quarter 2023 results: US$0.006 loss per share (further deteriorated from US$0.005 loss in 2Q 2022). Revenue: US$2.75m (up 228% from 2Q 2022). Net loss: US$2.85m (loss widened 20% from 2Q 2022).공시 • Aug 25BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023BioHarvest Sciences Inc. announced that they will report Q2, 2023 results on Aug 30, 2023공시 • Jul 08BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in fundingBioHarvest Sciences Inc. announced a non-brokered private placement of convertible notes for the gross proceeds of CAD 4,625,102.87 on July 7, 2023. The notes will have a term of 12 months, and pay interest of 9% per annum. The Convertible Notes are convertible as to principal and accrued interest at the option of the holder into common shares of the company at a conversion price of CAD 0.20 per share.공시 • Jun 08BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory BoardBioHarvest Sciences announced that it has added Dr. John Paul SanGiovanni, world renowned nutritionist and Harvard-trained scientist, to its Medical and Scientific Advisory board. Dr. SanGiovanni will act as a liaison with the spheres of Academia, Industry, and Government, helping spread the promise and potential of Botanical Synthesis. His deep connections within Academic and research institutions will introduce BioHarvest's biotech capabilities to new potential research partners, and he will contribute his experience to help facilitate targeted applications for both US and European government grants.Reported Earnings • Jun 01First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)First quarter 2023 results: US$0.002 loss per share (improved from US$0.005 loss in 1Q 2022). Revenue: US$2.16m (up 209% from 1Q 2022). Net loss: US$752.0k (loss narrowed 65% from 1Q 2022).공시 • Jun 01Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023BioHarvest Sciences Inc. reiterated sales guidance for the year 2023. The company is reiterating revenue guidance of USD 17 million+ for the year.공시 • May 19BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023.Reported Earnings • Apr 30Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)Full year 2022 results: US$0.025 loss per share (further deteriorated from US$0.023 loss in FY 2021). Revenue: US$5.50m (up 162% from FY 2021). Net loss: US$11.2m (loss widened 14% from FY 2021).공시 • Feb 16BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic NeuritisBioHarvest Sciences Inc. announced a collaboration with the International Neurorehabilitation Institute (INI) in Lutherville, Maryland to perform a clinical trial to assess the capacity of its RGC composition to promote eye health. The study will be led by Dr. Daniel Becker, Director of the INI and Assistant Professor of Neurology at Johns Hopkins School of Medicine. RGC is a patented composition based on BioHarvest's Botanical-Synthesis technology, with consistency and quality that have potential to meet the criteria for being used as an Active Pharmaceutical Ingredient (API). The planned translational open-label clinical study will evaluate the impact of RGC on multiple sclerosis (MS)-related optic neuritis driven by inflammation. The study - the latest of several human clinical trials run by BioHarvest - aims to elucidate the mechanisms through which RGC impacts the disease by measuring anti-oxidative, detoxifying, and inflammatory biomarkers. The research team hypothesizes that RGC will result in positive changes to eye health by modulating a variety of biomarkers compared to baseline in the study participants. The next important step for this study is submission to an Institutional Review Board (IRB) to be followed by the study launch with 15-30 participants. The Multiple Sclerosis Foundation estimates more than 1 million people in the United States and about 2.5 million people worldwide have been diagnosed with MS, and some 200 new cases are diagnosed weekly in the US alone. While the root causes of MS are still unknown, there are definite links between genetic and select environmental factors.공시 • Jan 18Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of AdvisorsBioHarvest Sciences Inc. announces that effective immediately, Dr. George Garibaldi will serve on its Scientific Board of Advisors. Complementing a top-tier group that includes a significant array of expertise, Dr. Garibaldi brings BioHarvest 40 years of experience in drug development and understanding of the pharma industry. Dr. George Garibaldi is co-founder and President of Research and Development of Noema Pharma AG. He previously held leadership responsibilities in research and development in several major pharmaceutical companies, most recently serving as VP and Global Head of Clinical Neuroscience at F. Hoffmann-La Roche. Dr. Garibaldi trained in child psychiatry, statistics, and neuropsychopharmacology. During his tenure at Roche, he led the development of multiple therapies including OCREVUS (ocrelizumab), approved in 2017 for primary progressive and relapsing-remitting multiple sclerosis. Prior to Roche, he was Head of Psychiatry and Geriatric Psychiatry at Novartis and the Neuroscience Therapeutic Area Lead at Janssen Pharmaceuticals. Throughout his career, Dr. Garibaldi developed therapies for multiple conditions including Exelon (rivastigmine) in Alzheimer's disease, Fanapt (iloperidone) in schizophrenia, Risperdal Consta (risperidone long-acting injectable) in frequently relapsing patients with bipolar disorders, and Invega (paliperidone) in patients with schizoaffective disorder. He also led the regulatory submission and approval of Risperdal (risperidone) in autism spectrum disorders. Dr. Garibaldi serves as a peer reviewer for multiple scientific and medical journals and has authored more than 100 articles in peer-reviewed journals. He developed, validated and published a number of clinician- and patient-reported clinical outcomes including "The Readiness for Hospital Discharge Questionnaire in Schizophrenia", "The Patient Most Troubling Symptoms Scale in Anxiety and Depression", "The Readiness for Work Questionnaire in Schizophrenia" and "The Clinical Global Impression for Schizoaffective Disorder". Dr. Garibaldi is a board member of several biotech companies, a member of the American Academy of Child and Adolescent Psychiatry (AACAP), founder and past president of the International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) and former chairman of the International Society for CNS Drug Development (ISCDD). He is the recipient of multiple awards including the ISCDD Award for Innovation. Dr. Garibaldi is widely recognized by his peers as an innovative and collaborative leader guided by his dedication to developing novel therapies for patients. Dr. Garibaldi earned an M.D. from the faculty of medicine of Cairo University. He completed his residency in Child and General Psychiatry at the Rene Descartes Medical School, his studies in statistics and mathematical modeling at the University of Kremlin-Bictre, and his studies in Neuropsychopharmacology at the Piti Salptrire.Reported Earnings • Nov 29Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)Third quarter 2022 results: US$0.009 loss per share (further deteriorated from US$0.007 loss in 3Q 2021). Revenue: US$1.52m (up 136% from 3Q 2021). Net loss: US$3.92m (loss widened 29% from 3Q 2021).Board Change • Nov 16No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). VP of Investor Relations, Secretary & Director Dave Ryan is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)Second quarter 2022 results: US$0.005 loss per share (down from US$0.004 profit in 2Q 2021). Revenue: US$838.0k (up 102% from 2Q 2021). Net loss: US$2.38m (down 234% from profit in 2Q 2021).Reported Earnings • May 31First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)First quarter 2022 results: US$0.005 loss per share (up from US$0.016 loss in 1Q 2021). Revenue: US$699.0k (up 123% from 1Q 2021). Net loss: US$2.13m (loss narrowed 69% from 1Q 2021).Reported Earnings • Apr 30Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)Full year 2021 results: US$0.023 loss per share (down from US$0.019 loss in FY 2020). Revenue: US$2.10m (up 431% from FY 2020). Net loss: US$9.83m (loss widened 49% from FY 2020).Board Change • Apr 27No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). VP of Investor Relations, Secretary & Director Dave Ryan is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Dec 01Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: US$644.0k (up US$591.0k from 3Q 2020). Net loss: US$3.04m (loss widened 65% from 3Q 2020). Revenue was in line with analyst estimates.Reported Earnings • Sep 01Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$415.0k (up US$376.0k from 2Q 2020). Net income: US$1.79m (up US$3.16m from 2Q 2020).Reported Earnings • Jun 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: US$6.81m (loss widened US$6.54m from 1Q 2020).Reported Earnings • May 02Full year 2020 earnings releasedFull year 2020 results: Net loss: US$6.58m (loss widened 54% from FY 2019).주주 수익률8MV0DE Personal ProductsDE 시장7D-3.6%1.4%3.9%1Y-38.9%-11.0%2.6%전체 주주 수익률 보기수익률 대 산업: 8MV0은 지난 1년 동안 -11%의 수익을 기록한 German Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 8MV0은 지난 1년 동안 2.6%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is 8MV0's price volatile compared to industry and market?8MV0 volatility8MV0 Average Weekly Movement7.8%Personal Products Industry Average Movement5.2%Market Average Movement6.1%10% most volatile stocks in DE Market12.9%10% least volatile stocks in DE Market2.7%안정적인 주가: 8MV0는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 8MV0의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트n/a89Zaki Rakibwww.bioharvest.com는 이스라엘과 미국에서 생명공학 회사로 운영되고 있습니다. 이 회사는 건강기능식품과 제약 부문을 통해 운영됩니다. 이 회사는 고농도의 활성 성분을 함유한 식물 세포를 생산하기 위한 식물 합성 플랫폼 기술을 개발합니다.더 보기BioHarvest Sciences Inc. 기초 지표 요약BioHarvest Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?8MV0 기초 통계시가총액€75.16m순이익 (TTM)-€9.83m매출 (TTM)€30.20m2.5x주가매출비율(P/S)-7.6x주가수익비율(P/E)8MV0는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표8MV0 손익계산서 (TTM)매출US$35.16m매출원가US$14.24m총이익US$20.92m기타 비용US$32.36m순이익-US$11.44m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-0.50총이익률59.50%순이익률-32.54%부채/자본 비율10.9%8MV0의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 05:32종가2026/05/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioHarvest Sciences Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matthew HewittCraig-Hallum Capital Group LLCAmit DayalH.C. Wainwright & Co.Anthony VendettiMaxim Group1명의 분석가 더 보기
공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026
공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026
공시 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.
공시 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7
공시 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
공시 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.
공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2026 Results on May 14, 2026BioHarvest Sciences Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026
공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2025 Results on Mar 31, 2026BioHarvest Sciences Inc. announced that they will report Q4, 2025 results After-Market on Mar 31, 2026
공시 • Dec 05BioHarvest Sciences Inc. Announces Launch of VINIA Blood Flow Hydration ProductBioHarvest Sciences Inc. announced the U.S. launch of VINIA Blood Flow Hydration, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolyte Market. Better Hydration starts with Better Blood Flow. Following overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydation™? is now shipping nationwide and is available exclusively at Vinia.com, with free delivery across North America. This product introduces a breakthrough concept to the rapidly growing hydration market: Hydration Powered by the Blood Flow benefits of VINIA'sPiceid Resveratrol, marking VINIA Blood Flow Hydrated™? as the world's first hydration formula with the power of VINIA's rapid absorption Piceid Resveratrol - designed to work synergistically to improve the body's circulation system and more efficiently deliver fluids and electrolytes where the body needs it most. VINIA Blood flow goes one step further and improves How electrolytes and nutrients get delivered. Containing the finest sources of natural electrolytes, the solution is formulated with premium sodium from sea salt, potassium from coconut water, and magnesium from marine ocean beds. This electrolyte solution is powered by VINIA's unique red grape polyphenol complex (23mg), including rapid absorption Piceid Res Veratrol (6mg), which has been clinically shown to significantly increase arterial dilation, improving blood flow. Better blood flow ensures more efficient transportation of electrolytes and fluids to body's organs, muscles, and cells, right where they're needed most. A New Era in Blood Flow-Driven Hydration Science. Products undergo rigorous testing using ISO 17025 accredited methods to provide the highest level of assurance for athletes. Every order is backed by BioHarvest's 90-Day "Feel It or It's Free" Guarantee, the industry's strongest consumer promise. Customers can use every stick for 90 days. If they do not love the taste or feel the VINIA®? difference, VINIA®? will refund the full purchase price and cover return shipping. No questions asked. The company has announced that VINIA Blood Flow Hydization is now available to all online consumers for purchase on VINIA.com and will be available on Amazon.com by the end of December. In addition to being available direct-to-consumer via the company's established e-commerce channels, VINIA Blood Flow hydration will also be distributed via select "point-of-sweat" outlets, to service active consumers looking for premium health solutions.
공시 • Nov 07+ 1 more updateBioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million.BioHarvest Sciences Inc. has completed a Follow-on Equity Offering in the amount of $17.395 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,485,000 Price\Range: $7
공시 • Nov 05BioHarvest Sciences Inc. to Report Q3, 2025 Results on Nov 13, 2025BioHarvest Sciences Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
공시 • Oct 06BioHarvest Sciences Inc. announced that it has received CAD 0.553037 million in fundingOn October 6, 2025, BioHarvest Sciences Inc. closed the transaction.
공시 • Sep 24BioHarvest Sciences Inc. announced that it has received CAD 5.1 million in fundingBioHarvest Sciences Inc announced that it has completed a private placement and issued Convertible Notes for aggregate gross proceeds of CAD 5,100,000 on September 22, 2025.
공시 • Aug 04BioHarvest Sciences Inc. to Report Q2, 2025 Results on Aug 11, 2025BioHarvest Sciences Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 11, 2025
공시 • Jun 05BioHarvest Sciences Inc. Announces the Launch of VINIA® DailyChews 2X FormulaBioHarvest Sciences Inc. announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com. Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.
공시 • May 02BioHarvest Sciences Inc. to Report Q1, 2025 Results on May 15, 2025BioHarvest Sciences Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
공시 • Mar 17BioHarvest Sciences Inc. to Report Q4, 2024 Results on Mar 31, 2025BioHarvest Sciences Inc. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025
공시 • Jan 22Bioharvest Sciences Inc. Appoints Sharon Malka as Independent DirectorBioHarvest Sciences Inc. announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately. Sharon Malka brings a wealth of experience to BioHarvest, having held senior leadership positions with a number of international healthcare and technology companies. He is currently Chief Executive Officer of Dotz Nano Ltd., an Australian-based technology company focused on developing, manufacturing and commercializing advanced materials for diagnostics solutions. Mr. Sharon is currently on the Board of Directors of MediWound Limited, a Nasdaq-listed biopharmaceutical company, where he also previously served as both Chief Financial Officer and Chief Executive Officer. Prior to Mediwound, Sharon held the role of Partner at Variance Economic Consulting Ltd., a financial services consulting boutique focused on international technology company. Mr. Malka is a certified CPA and graduate of the Executive Education Program of Harvard Business School. He holds a B.Sc. in Business Administration and an M.B.A.
공시 • Nov 27BioHarvest Sciences Inc. Launches VINIA Superfood Functional Tea LineBioHarvest Sciences Inc. announced the launch of its highly anticipated VINIA infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA® supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals. Tens of thousands of subscribers take VINIA daily to improve blood flow as a supplement in capsule form or through VINIA® Superfood coffee, which increases their dilation of arteries, improving blood flow and enhancing their physical energy and mental alertness. Now consumers can experience those same blood flow improvements together with a cup of great tasting VINIA Superfood Tea, featuring four premium blends: Black Tea, Green Tea, Matcha Green Tea and Cranberry Hibiscus Herbal Tea. BioHarvest's VINIA® SuperFood Infused Teas - which contain the equivalent piceid resveratrol contained in one capsule of VINIA® - deliver superior science, efficacy and taste. Third party blind taste testing shows BioHarvest's VINIA® infused teas outperformed leading English Breakfast and Green Tea brands. All the tea used in the VINIA SuperFood Infused Teas lineup are sourced from Rainforest Alliance certified farms. BioHarvest will launch its VINIA® infused tea line across major channels starting, December 7th, following a VIP launch commencing on November 25, 2024 for select existing VINIA® subscribers.
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.2m free cash flow). Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding).
공시 • Oct 23+ 1 more updateBioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024BioHarvest Sciences Inc. announced that they will report Q3, 2024 results on Nov 14, 2024
공시 • Sep 20Bioharvest Sciences Inc. Announces Resignation of David Ryan as DirectorBioHarvest Sciences Inc. announced the resignation of David Ryan as a director of the Company. Mr. Ryan will remain a key member of the Company's management team, continuing to serve as Vice President of Investor Relations of the Company. Mr. Ryan resigned as a director of the Company in order for the Company to meet Nasdaq mandates to have a majority of independent directors in connection with its proposed application to list its common shares on the Nasdaq Stock Market.
Reported Earnings • Aug 30Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.042 loss per share (improved from US$0.21 loss in 2Q 2023). Revenue: US$6.03m (up 119% from 2Q 2023). Net loss: US$687.0k (loss narrowed 76% from 2Q 2023). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €91.2m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$3.2m). Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€91.2m market cap, or US$99.6m).
공시 • Jun 21BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in fundingBioHarvest Sciences Inc. announced a private placement of up to 697,350 units at a price of CAD 9.82 per unit for the gross proceeds of CAD 6,847,977 on June 21, 2024. Each unit includes one common share, one-quarter (1/4) of a CAD 10.50 warrant, and one-quarter (1/4) of an CAD 15.77 Warrant. The Company will pay cash commissions or finders fees of up to 5% of the cash proceeds of the offering.
Reported Earnings • Jun 05First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)First quarter 2024 results: US$0.48 loss per share (further deteriorated from US$0.057 loss in 1Q 2023). Revenue: US$5.34m (up 147% from 1Q 2023). Net loss: US$6.58m (loss widened US$5.83m from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.
Reported Earnings • May 02Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)Full year 2023 results: US$0.027 loss per share (further deteriorated from US$0.025 loss in FY 2022). Revenue: US$12.7m (up 131% from FY 2022). Net loss: US$12.6m (loss widened 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공시 • Apr 05BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024.
공시 • Jan 09BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024BioHarvest Sciences Inc. announced that they will report Q4, 2023 results on Mar 29, 2024
공시 • Dec 27BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in fundingOn December 27, 2023, BioHarvest Sciences Inc., closed the transaction. The company raised CAD 1,836,383.28 in its second and final tranche closing. As a part of the transaction, the company paid a total of CAD 53,247.54 as commissions or finder's fees associated with this final tranche. The transaction was oversubscribed by CAD 122,873.26.
공시 • Dec 14Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee ProductsBioHarvest Sciences Inc. announced that it has created a new "functional" coffee product line featuring VINIA Red Grape Superfood, its nutraceutical product.ens of thousands of subscribers take VINIA daily to improve blood flow, which enhances their physical energy and mental alertness, and now consumers can experience those same blood flow improvements conveniently together with one daily cup of great tasting VINIA Superfood coffee, now available at . These new VINIA coffee products are the first of three key delivery mechanisms implementing the 'VINIA Inside' Strategy. The BioHarvest Sciences Botanical Synthesis platform delivers non- GMO, fingerprint consistent plant cells with elicited levels of active phytochemicals not available in nature. All benefits and claims are supported by scientific studies and clinical trials. Superior Taste-- All product formulations are extensively taste-tested via blind quantitative taste test research versus market leaders. VINIA is clinically proven to significantly dilate arteries. It achieves this unique outcome by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which Act as a vasoconstrictor). BioHarvest currently has a Direct-to-Consumer focus, with 93% of VINIA sales occurring on VINIA.com being via subscription. BioHarvest also uses Amazon.com as a key channel to source new customers. Formulated by leading scientists and coffee connoisseurs, VINIA Superfood Coffee contains 100% premium Arabica beans and is infused with a matrix of the red grape polyphenols found in red wine, with zero alcohol. VINIA Superfood Coffee is available for online purchase in North America on company website. Each Medium Roast and Decaf VINIA Superfood Coffee Pod includes VINIA Red Grape Powder (23 mg of polyphenols including 6 mg of piceid resveratrol) which is equivalent to one VINIA capsule. VINIA® Superfood Coffee is compatible with Keurig and most single serve brewing systems. VINIA has no affiliation with Keurig Dr. Pepper Inc, "Keurig" and "K-Cup" is a registered trademark of Keurig Dr. Pepper Inc. VINIA Superfood functional coffees are expected to be available in 2024 in Nespresso compatible pods, and the Company has announced that it will add tea products to its Hot Beverages business, including black and green teas. The Company expects to release financial guidance on the new VINIA Superfood Coffee and Tea portfolio at the end of first quarter of 2024.
공시 • Nov 30Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023BioHarvest Sciences Inc. revised revenue guidance for the year 2023. The company expects total revenue for 2023 to fall 27% short of the USD 17 Million revenue guidance provided by the Company in early 2023.
Reported Earnings • Nov 30Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.009 loss in 3Q 2022)Third quarter 2023 results: US$0.004 loss per share (improved from US$0.009 loss in 3Q 2022). Revenue: US$3.24m (up 114% from 3Q 2022). Net loss: US$1.73m (loss narrowed 56% from 3Q 2022).
공시 • Nov 30BioHarvest Sciences Inc. Provides Revenue Guidance for the Fourth Quarter 2023BioHarvest Sciences Inc. provided revenue guidance for the fourth quarter 2023. For the fourth quarter 2023, the company revenue range guidance of USD 4.2 million - USD 4.5 million.
공시 • Oct 20BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in fundingBioHarvest Sciences Inc. announced a non-brokered private placement of convertible notes for the gross proceeds of CAD 12,000,000 on October 19, 2023. The notes will have a term of 24 months, and pay interest of 12% per annum. The convertible notes and accrued interest will be convertible at the option of the holder into common shares of the Issuer at a conversion price that is equal to the closing market price of the company’s common shares on the date of conversion less a discount of 20% but in any event, not less than CAD 0.24 per share or more than CAD 0.75 per share.
Reported Earnings • Sep 03Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)Second quarter 2023 results: US$0.006 loss per share (further deteriorated from US$0.005 loss in 2Q 2022). Revenue: US$2.75m (up 228% from 2Q 2022). Net loss: US$2.85m (loss widened 20% from 2Q 2022).
공시 • Aug 25BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023BioHarvest Sciences Inc. announced that they will report Q2, 2023 results on Aug 30, 2023
공시 • Jul 08BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in fundingBioHarvest Sciences Inc. announced a non-brokered private placement of convertible notes for the gross proceeds of CAD 4,625,102.87 on July 7, 2023. The notes will have a term of 12 months, and pay interest of 9% per annum. The Convertible Notes are convertible as to principal and accrued interest at the option of the holder into common shares of the company at a conversion price of CAD 0.20 per share.
공시 • Jun 08BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory BoardBioHarvest Sciences announced that it has added Dr. John Paul SanGiovanni, world renowned nutritionist and Harvard-trained scientist, to its Medical and Scientific Advisory board. Dr. SanGiovanni will act as a liaison with the spheres of Academia, Industry, and Government, helping spread the promise and potential of Botanical Synthesis. His deep connections within Academic and research institutions will introduce BioHarvest's biotech capabilities to new potential research partners, and he will contribute his experience to help facilitate targeted applications for both US and European government grants.
Reported Earnings • Jun 01First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)First quarter 2023 results: US$0.002 loss per share (improved from US$0.005 loss in 1Q 2022). Revenue: US$2.16m (up 209% from 1Q 2022). Net loss: US$752.0k (loss narrowed 65% from 1Q 2022).
공시 • Jun 01Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023BioHarvest Sciences Inc. reiterated sales guidance for the year 2023. The company is reiterating revenue guidance of USD 17 million+ for the year.
공시 • May 19BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023.
Reported Earnings • Apr 30Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)Full year 2022 results: US$0.025 loss per share (further deteriorated from US$0.023 loss in FY 2021). Revenue: US$5.50m (up 162% from FY 2021). Net loss: US$11.2m (loss widened 14% from FY 2021).
공시 • Feb 16BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic NeuritisBioHarvest Sciences Inc. announced a collaboration with the International Neurorehabilitation Institute (INI) in Lutherville, Maryland to perform a clinical trial to assess the capacity of its RGC composition to promote eye health. The study will be led by Dr. Daniel Becker, Director of the INI and Assistant Professor of Neurology at Johns Hopkins School of Medicine. RGC is a patented composition based on BioHarvest's Botanical-Synthesis technology, with consistency and quality that have potential to meet the criteria for being used as an Active Pharmaceutical Ingredient (API). The planned translational open-label clinical study will evaluate the impact of RGC on multiple sclerosis (MS)-related optic neuritis driven by inflammation. The study - the latest of several human clinical trials run by BioHarvest - aims to elucidate the mechanisms through which RGC impacts the disease by measuring anti-oxidative, detoxifying, and inflammatory biomarkers. The research team hypothesizes that RGC will result in positive changes to eye health by modulating a variety of biomarkers compared to baseline in the study participants. The next important step for this study is submission to an Institutional Review Board (IRB) to be followed by the study launch with 15-30 participants. The Multiple Sclerosis Foundation estimates more than 1 million people in the United States and about 2.5 million people worldwide have been diagnosed with MS, and some 200 new cases are diagnosed weekly in the US alone. While the root causes of MS are still unknown, there are definite links between genetic and select environmental factors.
공시 • Jan 18Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of AdvisorsBioHarvest Sciences Inc. announces that effective immediately, Dr. George Garibaldi will serve on its Scientific Board of Advisors. Complementing a top-tier group that includes a significant array of expertise, Dr. Garibaldi brings BioHarvest 40 years of experience in drug development and understanding of the pharma industry. Dr. George Garibaldi is co-founder and President of Research and Development of Noema Pharma AG. He previously held leadership responsibilities in research and development in several major pharmaceutical companies, most recently serving as VP and Global Head of Clinical Neuroscience at F. Hoffmann-La Roche. Dr. Garibaldi trained in child psychiatry, statistics, and neuropsychopharmacology. During his tenure at Roche, he led the development of multiple therapies including OCREVUS (ocrelizumab), approved in 2017 for primary progressive and relapsing-remitting multiple sclerosis. Prior to Roche, he was Head of Psychiatry and Geriatric Psychiatry at Novartis and the Neuroscience Therapeutic Area Lead at Janssen Pharmaceuticals. Throughout his career, Dr. Garibaldi developed therapies for multiple conditions including Exelon (rivastigmine) in Alzheimer's disease, Fanapt (iloperidone) in schizophrenia, Risperdal Consta (risperidone long-acting injectable) in frequently relapsing patients with bipolar disorders, and Invega (paliperidone) in patients with schizoaffective disorder. He also led the regulatory submission and approval of Risperdal (risperidone) in autism spectrum disorders. Dr. Garibaldi serves as a peer reviewer for multiple scientific and medical journals and has authored more than 100 articles in peer-reviewed journals. He developed, validated and published a number of clinician- and patient-reported clinical outcomes including "The Readiness for Hospital Discharge Questionnaire in Schizophrenia", "The Patient Most Troubling Symptoms Scale in Anxiety and Depression", "The Readiness for Work Questionnaire in Schizophrenia" and "The Clinical Global Impression for Schizoaffective Disorder". Dr. Garibaldi is a board member of several biotech companies, a member of the American Academy of Child and Adolescent Psychiatry (AACAP), founder and past president of the International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) and former chairman of the International Society for CNS Drug Development (ISCDD). He is the recipient of multiple awards including the ISCDD Award for Innovation. Dr. Garibaldi is widely recognized by his peers as an innovative and collaborative leader guided by his dedication to developing novel therapies for patients. Dr. Garibaldi earned an M.D. from the faculty of medicine of Cairo University. He completed his residency in Child and General Psychiatry at the Rene Descartes Medical School, his studies in statistics and mathematical modeling at the University of Kremlin-Bictre, and his studies in Neuropsychopharmacology at the Piti Salptrire.
Reported Earnings • Nov 29Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)Third quarter 2022 results: US$0.009 loss per share (further deteriorated from US$0.007 loss in 3Q 2021). Revenue: US$1.52m (up 136% from 3Q 2021). Net loss: US$3.92m (loss widened 29% from 3Q 2021).
Board Change • Nov 16No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). VP of Investor Relations, Secretary & Director Dave Ryan is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)Second quarter 2022 results: US$0.005 loss per share (down from US$0.004 profit in 2Q 2021). Revenue: US$838.0k (up 102% from 2Q 2021). Net loss: US$2.38m (down 234% from profit in 2Q 2021).
Reported Earnings • May 31First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)First quarter 2022 results: US$0.005 loss per share (up from US$0.016 loss in 1Q 2021). Revenue: US$699.0k (up 123% from 1Q 2021). Net loss: US$2.13m (loss narrowed 69% from 1Q 2021).
Reported Earnings • Apr 30Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)Full year 2021 results: US$0.023 loss per share (down from US$0.019 loss in FY 2020). Revenue: US$2.10m (up 431% from FY 2020). Net loss: US$9.83m (loss widened 49% from FY 2020).
Board Change • Apr 27No independent directorsThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). VP of Investor Relations, Secretary & Director Dave Ryan is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Dec 01Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: US$644.0k (up US$591.0k from 3Q 2020). Net loss: US$3.04m (loss widened 65% from 3Q 2020). Revenue was in line with analyst estimates.
Reported Earnings • Sep 01Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$415.0k (up US$376.0k from 2Q 2020). Net income: US$1.79m (up US$3.16m from 2Q 2020).
Reported Earnings • Jun 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: US$6.81m (loss widened US$6.54m from 1Q 2020).
Reported Earnings • May 02Full year 2020 earnings releasedFull year 2020 results: Net loss: US$6.58m (loss widened 54% from FY 2019).
